Which has stronger earnings & valuation, SCPS or PXMD?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A PaxMedica N/A N/A -$18.29M -$6.09 N/A

Is SCPS or PXMD more profitable?

Scopus BioPharma's return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A PaxMedica N/A -3,167.89% -560.35%

Do analysts rate ADTX or PXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PaxMedica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, ADTX or PXMD?

PaxMedica is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt N/A N/A -$41.71M -$100.79 thousand N/A PaxMedica N/A N/A -$18.29M -$6.09 N/A

Is ADTX or PXMD more profitable?

PaxMedica has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets Aditxt -360,152.50% -374.60% -105.93% PaxMedica N/A -3,167.89% -560.35%

Which has higher earnings & valuation, ARDS or PXMD?

PaxMedica is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aridis Pharmaceuticals N/A N/A -$30.37M $0.09 0.00 PaxMedica N/A N/A -$18.29M -$6.09 N/A

Is ARDS or PXMD more profitable?

Aridis Pharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A PaxMedica N/A -3,167.89% -560.35%

Is NAVB or PXMD more profitable?

Navidea Biopharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A PaxMedica N/A -3,167.89% -560.35%

Which has stronger earnings & valuation, PXMD or EVLO?

PaxMedica is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PaxMedica N/A N/A -$18.29M -$6.09 N/A Evelo Biosciences N/A N/A -$114.53M -$8.81 N/A

Is PXMD or EVLO more profitable?

Evelo Biosciences' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Evelo Biosciences N/A N/A N/A

PaxMedica (PXMD) Competitors

$0.0007 0.00 (0.00%)

As of 06/12/2026 02:16 PM Eastern

Compare

PXMD vs. SCPS, ADTX, ARDS, NAVB, and EVLO

Should you buy PaxMedica stock or one of its competitors? MarketBeat compares PaxMedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PaxMedica include Scopus BioPharma (SCPS), Aditxt (ADTX), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical products" industry.

How does PaxMedica compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

In the previous week, Scopus BioPharma had 1 more articles in the media than PaxMedica. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for PaxMedica. Scopus BioPharma's average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
PaxMedica	Neutral

4.9% of PaxMedica shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 1.0% of PaxMedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A

Scopus BioPharma's return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
PaxMedica	N/A	-3,167.89%	-560.35%

Scopus BioPharma has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market.

Summary

Scopus BioPharma beats PaxMedica on 6 of the 7 factors compared between the two stocks.

How does PaxMedica compare to Aditxt?

Aditxt (NASDAQ:ADTX) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 1.0% of PaxMedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Aditxt had 8 more articles in the media than PaxMedica. MarketBeat recorded 8 mentions for Aditxt and 0 mentions for PaxMedica. Aditxt's average media sentiment score of 0.72 beat PaxMedica's score of 0.00 indicating that Aditxt is being referred to more favorably in the media.

Company	Overall Sentiment
Aditxt	Positive
PaxMedica	Neutral

Aditxt has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PaxMedica	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PaxMedica has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
PaxMedica	N/A	-3,167.89%	-560.35%

PaxMedica is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	N/A	N/A	-$41.71M	-$100.79 thousand	N/A
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A

Summary

Aditxt beats PaxMedica on 8 of the 12 factors compared between the two stocks.

How does PaxMedica compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
PaxMedica	Neutral

Aridis Pharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
PaxMedica	N/A	-3,167.89%	-560.35%

PaxMedica is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	0.00
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of PaxMedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aridis Pharmaceuticals has a beta of 44.97, indicating that its stock price is 4,397% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market.

Summary

Aridis Pharmaceuticals beats PaxMedica on 7 of the 8 factors compared between the two stocks.

How does PaxMedica compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 1.0% of PaxMedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

Navidea Biopharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
PaxMedica	N/A	-3,167.89%	-560.35%

Navidea Biopharmaceuticals has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
PaxMedica	Neutral

Summary

Navidea Biopharmaceuticals beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does PaxMedica compare to Evelo Biosciences?

PaxMedica (NASDAQ:PXMD) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Evelo Biosciences	Neutral

PaxMedica is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Evelo Biosciences	N/A	N/A	-$114.53M	-$8.81	N/A

Evelo Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Evelo Biosciences	N/A	N/A	N/A

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Evelo Biosciences beats PaxMedica on 5 of the 8 factors compared between the two stocks.

Get PaxMedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PXMD vs. The Competition

Export

Metric	PaxMedica	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8K	$979.54M	$6.52B	$12.05B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	0.00	1.45	24.00	24.42
Price / Sales	N/A	120.49	515.84	118.72
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	0.00	7.85	10.60	6.82
Net Income	-$18.29M	-$4.88M	$3.57B	$337.56M
7 Day Performance	N/A	0.64%	0.59%	1.16%
1 Month Performance	N/A	-0.16%	1.54%	3.16%
1 Year Performance	N/A	47.51%	25.41%	30.60%

PaxMedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PXMD PaxMedica	N/A	$0.00 flat	N/A	+600.0%	$8K	N/A	N/A	2	Gap Down
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	+33.3%	$17K	N/A	N/A	9	Gap Up
ADTX Aditxt	1.0226 of 5 stars	$0.01 +3.8%	N/A	-100.0%	$11K	N/A	N/A	60	Gap Down High Trading Volume
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	+100.0%	$11K	N/A	0.00	30
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PXMD) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PaxMedica (PXMD) Competitors

PXMD vs. SCPS, ADTX, ARDS, NAVB, and EVLO

How does PaxMedica compare to Scopus BioPharma?

Summary

How does PaxMedica compare to Aditxt?

Summary

How does PaxMedica compare to Aridis Pharmaceuticals?

Summary

How does PaxMedica compare to Navidea Biopharmaceuticals?

Summary

How does PaxMedica compare to Evelo Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PXMD vs. The Competition

PaxMedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PaxMedica (PXMD) Competitors

PXMD vs. SCPS, ADTX, ARDS, NAVB, and EVLO

How does PaxMedica compare to Scopus BioPharma?

Does the media refer more to SCPS or PXMD?

Do institutionals and insiders have more ownership in SCPS or PXMD?

Which has stronger earnings & valuation, SCPS or PXMD?

Is SCPS or PXMD more profitable?

Which has more risk & volatility, SCPS or PXMD?

Summary

How does PaxMedica compare to Aditxt?

Do institutionals and insiders have more ownership in ADTX or PXMD?

Does the media prefer ADTX or PXMD?

Which has more volatility & risk, ADTX or PXMD?

Do analysts rate ADTX or PXMD?

Is ADTX or PXMD more profitable?

Which has better earnings and valuation, ADTX or PXMD?

Summary

How does PaxMedica compare to Aridis Pharmaceuticals?

Does the media favor ARDS or PXMD?

Is ARDS or PXMD more profitable?

Which has higher earnings & valuation, ARDS or PXMD?

Do insiders & institutionals hold more shares of ARDS or PXMD?

Which has more risk and volatility, ARDS or PXMD?

Summary

How does PaxMedica compare to Navidea Biopharmaceuticals?

Do insiders & institutionals have more ownership in NAVB or PXMD?

Which has more risk & volatility, NAVB or PXMD?

Is NAVB or PXMD more profitable?

Which has higher earnings and valuation, NAVB or PXMD?

Does the media refer more to NAVB or PXMD?

Summary

How does PaxMedica compare to Evelo Biosciences?

Which has more volatility & risk, PXMD or EVLO?

Does the media favor PXMD or EVLO?

Which has stronger earnings & valuation, PXMD or EVLO?

Is PXMD or EVLO more profitable?

Do institutionals and insiders have more ownership in PXMD or EVLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PXMD vs. The Competition

PaxMedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools